MetaCap

Regeneron Pharmaceuticals (REGN) vs Royalty Pharma (RPRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Royalty Pharma (RPRX) has outperformed Regeneron Pharmaceuticals (REGN) over the past year, gaining 75.9% versus a gain of 21.8%. Over five years, RPRX leads with a +63.4% price change compared with +43.1% for REGN. Regeneron Pharmaceuticals is the larger company by market cap ($95.24 billion vs $39.36 billion), about 2.4 times the size, while Royalty Pharma is growing revenue faster (+5.1% vs +1.0%).

On valuation, Royalty Pharma trades at a lower forward P/E (11.6x vs 12.8x for Regeneron Pharmaceuticals). Royalty Pharma offers the higher dividend yield (1.35% vs 0.40%). Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus 31.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

REGN+21.80%RPRX+75.87%
+85%+30%-26%
Nov 21, 20251 yearNov 20, 2026
REGN+41.06%RPRX+64.70%
+90%+22%-46%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

REGN versus RPRX key metrics
MetricREGNRPRX
Share price$920.69$68.45
Market cap$95.24B$39.36B
1-day change-0.19%+1.08%
YTD return+19.28%+77.15%
1-year return+21.80%+75.87%
5-year return+43.11%+63.40%
P/E ratio (TTM)20.3544.74
Forward P/E12.8511.62
EPS (TTM)$45.24$1.53
Dividend yield0.40%1.35%
Annual dividend$3.70$0.925
Revenue (latest FY)$14.34B$2.38B
Revenue growth (YoY)+0.99%+5.06%
Net income (latest FY)$4.50B$770.95M
Operating margin24.95%65.58%
Net margin31.41%32.42%
52-week high$991.73$70.37
52-week low$591.52$37.31
Distance from 52-week high-7.16%-2.73%
Analyst consensusbuybuy
Avg. price target upside+7.64%+9.93%
Average volume805.45K3.21M
Shares outstanding101.63M445.27M
Employees15,410100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Regeneron Pharmaceuticals is about 2.4 times larger than Royalty Pharma by market value ($95.24B vs $39.36B).
  • RPRX has outperformed REGN by 54.1 percentage points over the past year.
  • Royalty Pharma trades at a higher earnings multiple (44.7x vs 20.4x trailing P/E).

About Regeneron Pharmaceuticals

REGN stock →

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees

About Royalty Pharma

RPRX stock →

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

REGN vs RPRX FAQ

Which is bigger, Regeneron Pharmaceuticals or Royalty Pharma?

Regeneron Pharmaceuticals (REGN) is larger, with a market capitalization of $95.24B compared with $39.36B for Royalty Pharma (RPRX).

Which stock has performed better over the past year, REGN or RPRX?

RPRX returned +75.87% over the past 12 months, compared with +21.80% for REGN (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, REGN or RPRX?

REGN has the lower trailing P/E at 20.4, versus 44.7 for RPRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Regeneron Pharmaceuticals or Royalty Pharma?

Royalty Pharma has the higher yield at 1.35%, compared with 0.40% for Regeneron Pharmaceuticals.

Are Regeneron Pharmaceuticals and Royalty Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons